share_log

Swelling Losses Haven't Held Back Gains for Ocular Therapeutix (NASDAQ:OCUL) Shareholders Since They're up 302% Over 1 Year

Swelling Losses Haven't Held Back Gains for Ocular Therapeutix (NASDAQ:OCUL) Shareholders Since They're up 302% Over 1 Year

腫脹的損失並沒有阻止眼科治療 (納斯達克:OCUL) 的股東獲利,因爲他們在一年內漲幅達到302%
Simply Wall St ·  11/17 07:54

Ocular Therapeutix, Inc. (NASDAQ:OCUL) shareholders have seen the share price descend 19% over the month. But that isn't a problem when you consider how the share price has soared over the last year. In that time, shareholders have had the pleasure of a 302% boost to the share price. So we wouldn't blame sellers for taking some profits. Of course, winners often do keep winning, so there may be more gains to come (if the business fundamentals stack up).

ocular therapeutix, Inc. (納斯達克:OCUL) 股東在過去一個月中看到股價下降了19%。但考慮到過去一年股價的飆升,這並不是一個問題。在此期間,股東們欣喜地見證了股價上漲302%。因此,我們不會責怪賣方兌現一些利潤。當然,贏家往往會繼續獲勝,所以未來可能會有更多的收益(如果業務基本面堆積起來的話)。

Although Ocular Therapeutix has shed US$291m from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.

儘管ocular therapeutix本週從其市值中損失了29100萬美元,但我們來看看它長期的基本面趨勢,看看它們是否推動了回報。

Because Ocular Therapeutix made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

由於ocular therapeutix在過去12個月中出現了虧損,我們認爲市場可能更關注營業收入和營業收入增長,至少目前是這樣。當一家公司沒有盈利時,我們通常希望看到良好的營業收入增長。這是因爲如果營業收入增長微不足道,而且從未盈利,我們很難對公司是否能保持可持續性有信心。

Over the last twelve months, Ocular Therapeutix's revenue grew by 6.5%. That's not a very high growth rate considering it doesn't make profits. So the 302% gain in just twelve months is completely unexpected. We're happy that investors have made money, but we can't help questioning whether the rise is sustainable. It just goes to show that big money can be made if you buy the right stock early.

在過去12個月中,ocular therapeutix 的營業收入增長了6.5%。鑑於它沒有盈利,這並不是一個非常高的增長率。因此,僅在12個月內增長302%是完全意料之外的。我們很高興投資者賺錢了,但我們忍不住懷疑這一增長是否可持續。這恰恰表明,如果你早期買對股票,可以賺到大錢。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

以下圖像顯示了公司的營業收入和盈利(隨時間變化)(單擊以查看準確的數字)。

big
NasdaqGM:OCUL Earnings and Revenue Growth November 17th 2024
納斯達克GM:OCUL 業績和營業收入增長 2024年11月17日

This free interactive report on Ocular Therapeutix's balance sheet strength is a great place to start, if you want to investigate the stock further.

這份關於ocular therapeutix資產負債表強度的免費互動報告是一個很好的開始,如果你想進一步調查這隻股票。

A Different Perspective

另一種看法

It's nice to see that Ocular Therapeutix shareholders have received a total shareholder return of 302% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 24% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for Ocular Therapeutix (of which 1 can't be ignored!) you should know about.

很高興看到ocular therapeutix的股東在過去一年中獲得了302%的總股東回報。由於一年期的總股東回報率優於五年期的總股東回報率(後者爲每年24%),看起來這隻股票的表現最近有所改善。鑑於股價動量保持強勁,可能值得仔細研究這隻股票,以免錯過機會。雖然考慮市場條件對股價可能產生的不同影響是非常重要的,但還有其他更爲重要的因素。例如風險。每家公司都有風險,我們發現了ocular therapeutix的3個警示信號(其中1個不能被忽視!)你應該知道。

Of course Ocular Therapeutix may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,ocular therapeutix可能不是最佳的買入股票。因此你可能希望查看這份免費的成長股集合。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論